The Guggenheim analyst's reiteration of a Buy rating and maintaining a $110 price target on Axsome Therapeutics (AXSM) is a positive signal for the stock. This reaffirms the analyst's confidence in the company's potential and could lead to increased investor interest, potentially driving the stock price up in the short term.